small molecule

BREO ELLIPTA

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

Loss of exclusivityApril 2031latest FDA-listed patent expiry

CompanyGLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE

Drug detail

Brand name	BREO ELLIPTA
Active ingredient	FLUTICASONE FUROATE; VILANTEROL TRIFENATATE
Strength	0.1MG/INH;EQ 0.025MG BASE/INH
Dosage form	POWDER
Route	INHALATION
Modality	Small molecule
FDA approval	May 2013
Marketing status	RX

Listed patents

Patent	Expires	Type
8746242*PED	April 2031	—
8746242	October 2030	product
8534281*PED	September 2030	—
8534281	March 2030	product
11116721*PED	August 2029	—
11116721	February 2029	product
8511304*PED	December 2027	—
8511304	June 2027	product

Regulatory exclusivity

Code	Expires
PED	November 2026
NPP	May 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE